Cargando…

Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis

Detalles Bibliográficos
Autores principales:	Campa, Molly, Mansouri, Bobbak, Warren, Richard B., Menter, Alan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906106/ https://www.ncbi.nlm.nih.gov/pubmed/27025713 http://dx.doi.org/10.1007/s13555-016-0112-y

Ejemplares similares

A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2015)

New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors
por: Gaspari, Anthony A, et al.
Publicado: (2015)

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
Publicado: (2021)

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
por: Kivelevitch, Dario, et al.
Publicado: (2014)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
por: Haugh, Isabel M, et al.
Publicado: (2018)

Erratum to: Letter from the Editors
por: Menter, Alan, et al.
Publicado: (2016)

Serum Levels of TNF-α, IL-12/23p40, and IL-17 in Plaque Psoriasis and Their Correlation with Disease Severity
por: Kyriakou, Aikaterini, et al.
Publicado: (2014)

Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
por: Adsit, Sandra, et al.
Publicado: (2017)

IL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients
por: Shi, Yuling, et al.
Publicado: (2019)

The role of IL‐23 and the IL‐23/T(H)17 immune axis in the pathogenesis and treatment of psoriasis
por: Girolomoni, G., et al.
Publicado: (2017)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
por: Hanley, Tessa L, et al.
Publicado: (2017)

An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis
por: Kutwin, Magdalena, et al.
Publicado: (2021)

The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review
por: Tsiogka, Aikaterini, et al.
Publicado: (2023)

Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
por: Yang, Eric J, et al.
Publicado: (2019)

The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis
por: Nyholm, Nanna, et al.
Publicado: (2023)

Erratum, Volume 17, July 23, 2020 Release
Publicado: (2020)

IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-Type Psoriasis in Brazilian Patients
por: de Oliveira, Priscilla Stela Santana, et al.
Publicado: (2015)

Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis
por: Miyagawa, Hanae, et al.
Publicado: (2021)

Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors
por: Huang, Yu-Huei, et al.
Publicado: (2023)

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Bai, Fan, et al.
Publicado: (2019)

Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis
por: Li, Qian, et al.
Publicado: (2022)

The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
por: Brembilla, Nicolo Costantino, et al.
Publicado: (2018)

The role of IL-23 in the immunopathogenesis of psoriasis
por: Meglio, Paola Di, et al.
Publicado: (2010)

Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
por: Fargnoli, Maria Concetta
Publicado: (2019)

Erratum: Attenuation of Allergen-, IL-13–, and TGF-α–induced Lung Fibrosis after the Treatment of rIL-15 in Mice
Publicado: (2021)

Comment on: Drug Survival of IL‑12/23, IL‑17 and IL‑23 Inhibitors for Psoriasis Treatment: A Retrospective Multi‑Country, Multicentric Cohort Study
por: Borg, Emma, et al.
Publicado: (2021)

Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study
por: Huang, Dawei, et al.
Publicado: (2023)

Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
por: Yang, Kevin, et al.
Publicado: (2020)

Role of subnetworks mediated by [Formula: see text] , IL-23/IL-17 and IL-15 in a network involved in the pathogenesis of psoriasis
por: Pandey, Rakesh, et al.
Publicado: (2021)

Biological and genetic evaluation of IL-23/IL-17 pathway in ankylosing spondylitis patients
por: DEVECI, HULYA, et al.
Publicado: (2020)

The Role of IL-17 Cytokines in Psoriasis
por: Mosca, Megan, et al.
Publicado: (2021)

Association between IL-17F, IL-17RA Gene Polymorphisms and Response to Biological Drugs in Psoriasis and Beyond
por: Pușcaș, Alexandra Dana, et al.
Publicado: (2023)

Increased IL17A, IFNG, and FOXP3 Transcripts in Moderate-Severe Psoriasis: A Major Influence Exerted by IL17A in Disease Severity
por: de Oliveira, Priscilla Stela Santana, et al.
Publicado: (2016)

Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
por: Boutet, Marie-Astrid, et al.
Publicado: (2018)

Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer
por: Quatresooz, Pascale, et al.
Publicado: (2012)

Targeting IL-23 in psoriasis: current perspectives
por: Fotiadou, Christina, et al.
Publicado: (2018)

Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis
por: Crowley, J.J., et al.
Publicado: (2019)

Erratum: Vol. 66, No. 23
Publicado: (2017)

Erratum: Vol. 70, No. 23
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rbemg2vusov4pjoeaavsrb34c6